Multimodal leukemia, young female doctor talking to an older male patient, oncology, Clinical genomics
Oncology | Blood Cancer

All-in-one, simplified blood cancer profiling

Accurate and comprehensive molecular profiling is essential

The number of genes that need to be sequenced for blood cancer research has dramatically increased over the past few decades. More, to get accurate results, there must be no compromise on performance, especially when profiling challenging regions.

Current approaches require two separate workflows to prepare libraries from separate DNA and RNA isolates. But analyzing blood cancers with multiple sequencing tests and disparate workflows creates resource inefficiencies and lengthens turnaround times.

A rapid, multimodal NGS solution is a must-have.

With the QIAseq Leukemia Multimodal Panel, you can perform your leukemia NGS analyses in one workflow. 
Workflow Benefits
  • The ONLY single consolidated workflow for simultaneous
    DNA + RNA library prep using total nucleic acids as input 
  • Increased lab efficiency with a 50% reduction in user interventions
Results
  • Confident detection of low-frequency variants (JAK2 and KIT
    at 1% VAF and KIT D816V at 0.4% VAF)
  • Detection of large InDels, such as CALR type 1 (52 bp del)
    and FLT3 ITDs
  •  Detection of both known and novel fusions
  •  Full coverage of GC-rich regions, such as CEBPA
  •  Calling of homopolymer regions, such as for the
    ASXL1homopolymeric p.G646fs*12 variant
Need more info about this All-in-One solution?
To learn more about the QIAseq Leukemia Multimodal Panel and other related products

Comprehensive genomic profiling approach for myeloid neoplasms

Listen to Dr. Vincent Funari talk about how a comprehensive genomic profiling approach was successfully used for myeloid neoplasms.
Dr. Vincent Funari webinar speaker for oncohematology summit

QIAseq Multimodal Pan Cancer Panel

The QIAseq Pan-cancer Multimodal Panel enables simultaneous enrichment and profiling of 605 relevant DNA variant and RNA fusion biomarkers found across multiple cancers, as well as assessment of tumor mutational burden (TMB) and microsatellite instability (MSI), from a single sample input of 10 ng.

QIAseq Targeted DNA Pro Human Myeloid Neoplasms Research Panel

The Human Myeloid Neoplasms Research QIAseq® Targeted DNA Pro Panel is a complete Sample to Insight NGS solution for myeloid neoplasms analysis.

RNA Fusion XP Leukemia Panel

Applying digital RNA sequencing to scan for known and novel fusion genes.

QCI®️ Secondary Analysis

QCI Secondary Analysis is a new cloud-based service for NGS secondary analysis powered by DNAnexus, the world’s most secure and trusted platform for biomedical data analysis.

QCI Interpret for QIAseq

Connected to the exclusive QIAGEN KnowledgeBase, the industry’s most comprehensive, manually curated resource that is updated weekly, QCI Interpret for QIAseq dynamically computes pathogenicity based on the AMP/ASCO/CAP or ACMG/AMP guidelines for every variant in over 31,000 cancer types with full transparency.